Kyowa Hakko Kirin Co., Limited

Dicerna Pharmaceuticals, Inc.

Toshihiko Ishii

Miyoko Asano

Kenya Shitara

Shiro Akinaga

Rinpei Niwa

So Ohta

Junji Kanazawa

Takeshi Kuboyama

Tomoyuki Naoi

Yuka Sasaki

Junichi Enokizono

Yuka Sakai

Akihiro Tokunaga

Kentarou Hatanaka

The present invention provides a composition for suppressing the expression of a KRAS gene, comprising a lipid particle containing, as a drug, a double-stranded nucleic acid having an antisense strand having a sequence of bases complementary to the sequence of at least 19 continuous bases of any one KRAS gene's mRNA of sequence Nos. 1 to 3; and a cationic lipid represented by the following formula (I): wherein  

RNAi pharmaceutical composition for suppressing expression of KRAS gene

A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.

Medicament comprising recombinant antibody against chemokine receptor CCR4

A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.

Pharmaceutical composition comprising antibody composition which specifically binds to CCR4

Growing community of inventors

Shizuoka, Japan

Toshihiko Ishii